Credilabs Launches Private Credit Vault on Enzyme Protocol

Enzyme Protocol is partnering with Rayls Labs as a launch partner, bringing institutional-grade tokenized fund infrastructure to the platform from day one. **Key Details:** - Enzyme's Onyx and Myso products will be available on Rayls at launch - The partnership provides institutional-grade infrastructure for tokenized funds - Onyx enables fund managers to access lending markets like Morpho and Fluid directly within tokenized fund structures This collaboration aims to reduce infrastructure constraints for early-stage investment opportunities while maintaining institutional standards. Read the full announcement: [Enzyme arrives on Rayls](https://enzyme.finance/blog-posts/enzyme-arrives-on-rayls)

**Enzyme Onyx** addresses different protocol needs across three key stages: - **Pre-TGE**: Early participation incentives to build community - **Post-TGE**: Strengthen Total Value Locked (TVL) after token launch - **Mature stage**: Manage liquidity across multiple assets including stablecoins and liquid staking tokens The platform provides structured, on-chain strategies that protocols can adopt when timing is right for their development phase. Each stage requires different tooling approaches, but most protocols eventually need comprehensive on-chain financial infrastructure. [Explore Onyx](https://enzyme.finance/products/onyx?utm_source=x&utm_medium=organic&utm_content=post)

**Multi-chain complexity solved**: As investment products expand across different blockchains, reporting becomes increasingly complex for asset managers. **Automated data sourcing**: Chainlink's CRE (Crypto Reporting Engine) automatically pulls and verifies NAV and performance data from: - On-chain sources - Centralized finance platforms - Traditional financial systems **Pain point addressed**: The solution eliminates manual reporting work that previously required tracking assets across multiple chains and platforms. **Verification built-in**: All data is automatically verified, reducing errors and ensuring accuracy for compliance and investor reporting.

Enzyme.Myso is advancing DeFi with institutional-grade on-chain options trading. The platform offers: - Native on-chain options strategies - Fully auditable transaction flows - Infrastructure designed for DAOs and institutions **Real-world implementation**: Compound DAO recently integrated covered calls into their treasury strategy using Enzyme.Myso, targeting approximately 15% APY while maintaining controlled risk exposure. This development signals a shift in how DAOs can optimize idle capital through sophisticated options strategies. *Learn more at* [Enzyme Finance](http://enzyme.finance/products/myso)

Major financial institutions are forecasting significant growth in tokenized assets: - Citi projects tokenized securities market could reach $45T by 2030 - WEF estimates 10% of global GDP could be blockchain-tokenized by 2027 - McKinsey reports shift from pilot to at-scale deployment Key trends expected in next cycle: - Shift to natively tokenized funds - Increased institutional adoption - Integration with DeFi infrastructure - Clearer regulatory framework Traditional finance faces challenges from outdated systems, while tokenized vehicles offer programmability and global accessibility. Enzyme Protocol is positioning to support this transition with native tokenization capabilities. [Learn more about tokenized funds](http://enzyme.finance/use-cases/tokenized-funds)